Ulcerative Colitis Clinical Trial
Official title:
The Efficacy and Tolerability of Coltect as Add-on in Patients With Active Ulcerative Colitis - an Open Label
The aim of the study is to reduce the severity and duration of acute attacks, to prevent the
recurrence of new acute attacks and to improve patient's quality of life.
Coltect contains anti inflammatory and antioxidant natural agents (curcumin, green tea and
selenomethionine) which are associated with a positive effect on inflammatory disease.
The investigators assume that Coltect represents a tolerable and mild treatment, viable
alternative to other medical therapies with fewer side effects.
Coltect is a food supplement that contains active ingredients from herbal sources.
Studies in animal models of colitis and in humans with IBD demonstrated that the components
of Coltect have anti-inflammatory effects:
Hanai H. et al demonstrated that curcumin was safe and effective in maintaining remission in
patients with quiescent UC. (7)
B.Salh et al showed that curcumin, was able to attenuate colitis in the dinitrobenzene
sulfonic acid (DNB)-induced murine model of colitis. The immunohistochemical signal is
dramatically attenuated at the level of the mucosa by curcumin. The authors thus proposed
that curcumin may have therapeutic implications for human IBD. (8)
Potential Benefits of Coltect- Coltect might be suited for the treatment of patients with
mild to moderate flare-ups of ulcerative colitis.
Coltect provides an effect with expected low incidence of side effects. (each agent tested
before and found safe for human use).
The availability of a safe and effective non-surgical and non steroids treatment of active
ulcerative colitis.
Overview - Clinical indication and summary of existing preclinical and clinical knowledge
pertaining to the product.
Coltect contains natural compounds: curcumin, green tea and selenium which are approved as
food supplements by the Ministry of Health in Israel. Curcumin and green tea are widely used
in the food industry.
Curcumin is a natural compound found in the plant Curcuma longa which is used as a food
additive known as turmeric. The major pigment in turmeric is curcumin - chemical name
diferuloymethane, which possesses both anti-inflammatory and antioxidant properties.
Curcumin also strongly inhibits proliferation of HT-29 and HCT-15 human colon cancer cell
lines (1). Dietary administration of curcumin suppresses the development of chemically
induced cancers(1). These properties have led to studies on the chemopreventive effects of
curcumin which also showed that the agent reduces colonic inflammatory responses.
Curcumin has a profound immunosuppressive effect via inhibition of IL-2 synthesis as well as
IL-2 and mitogen activation of human leukocytes. This immunosuppressive effect may be
mediated by NFκB inhibition (1).
Based on the aforementioned, curcumin appears to reduce the inflammatory response in
ulcerative colitis patients Clinical studies with curcumin have shown beneficial effects in
experimental studies of acute and chronic diseases characterized by an exaggerated
inflammatory reaction. There is an ample evidence to support its clinical use both in the
prevention and a treatment setting. Several natural substances such as curcumin have greater
antioxidant effects than conventional vitamins, including various polyphenols, flavonoids
and curcumenoids. Natural substances are worth further research both experimentally and
clinically.
Sting et al found that: Curcumin was shown to be non-toxic, to have antioxidant activity,
and to inhibit such mediators of inflammation such as NFkB, cyclooxygenase-2 (COX-2),
lipooxygenase (LOX), and inducible nitric oxide synthase (iNOS). (13)
Ricky A. Sharma et al designed a dose-escalation study to explore the pharmacology of
curcumin in humans. Patients with advanced colorectal cancer consumed capsules compatible
with curcumin doses between 0.45 and 3.6gr. daily for up to 4 months. Curcumin was well
tolerated at all of the dose levels, and dose-limiting toxicity was not observed. At dose of
3.6gr. mild diarrhea is only discernible toxicity. (2) Cheng et al. treated patients with
pre-malignant conditions with tablets containing pure curcumin for up to 3 months at daily
dose as high as 8gr. without evident toxicity . They recommended that the common therapeutic
dose would be 400-600 mg curcumin 3 times daily.(14)
Ricky el al showed that consumption of 3.6 g of curcumin daily causes inhibition of PGE2
production by blood leukocytes measured ex vivo.(2)
In therapy for UC, a double blind placebo-controlled trial with curcumin found that both the
clinical and endoscopic evaluation scores were significantly improved by curcumin therapy.
The endoscopic score was substantially improved compared with the placebo.
The results of this study indicate that the turmeric component, curcumin, is potentially a
promising medication for the treatment of IBD (7)
Green tea is made from unfermented, solely leaves of Camellia sinensis and contains the
highest concentration of powerful antioxidants called polyphenols.
The green tea polyphenols include (-)-epigallocatechin gallate (EGCG), (-) epigallocatechin
(EGC), (-)-epicatechin gallate (ECG) and (-)-epicatechin (EC), they have potent antioxidant
properties. (9) Gary et al provide evidence that green tea polyphenols have
anti-inflammatory effects in murine colitis. They showed that mice treated with green tea
polyphenols have less severe colitis, and green tea polyphenols are widely distributed
throughout the body, one of the highest tissue concentrations is found in the intestine.
This distribution favors its use in gastrointestinal diseases such as IBD.(9)
Selenium is an essential trace element with a worldwide average nutritional intake of 50 to
350 µg/d function as an antioxidant and anti inflammatory and associated with colorectal
cancer prevention.(10,11) Marwan et al established the safety of administering high dose
(2200 µg) of selenomethionine in humans with cancer up to 13 months. (12) Toxicity at high
dose selenium appeared as mild headache, nausea or heartburn.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |